TBET $1.50 Ceo kauft alle Aktien zu $3 auf!

Ticker: TBET
Preis: $1.50
http://www.dailyfinance.com/quote/nasdaq/...hares/tbet/key-statistics




 

TBET announces Intent to Go Private

Tibet Pharmaceuticals, Inc. Announces Intent to Go Private
Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that,

"In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders."

The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".

Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China and believes that additional distribution channels will help enhance its completive advantages in the industry.

About Tibet Pharmaceuticals, Inc.

Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News) is an emerging specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.

For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: White Paper, Investor Portal and Overview Video.

For more information on Tibet Pharmaceuticals, please visit: http://www.tibetpharmaceuticals.com/

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts.

These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:

Financial Communications Trilogy Capital Partners - AsiaDarren MintonPresidentToll-free: 800-592-6067info@trilogy-capital.com

SOURCE Tibet Pharmaceuticals, Inc.  

http://www.tibetpharmaceuticals.com/

http://www.tibetpharmaceuticals.com/pr.html  

http://seekingalpha.com/article/...rading-below-net-cash?source=yahoo

"Cash and cash equivalents increased from $7.6 million as of December 31, 2010 to $26.0 million as of September 30, 2011. The September 30, 2011 total reflects the receipt of proceeds of the company's January 24, 2011 initial public offering of three million shares of its common stock at an offering price of $5.50."  

werde das ganze beobachten.  

CEO Hong Yu To Take Tibet Pharma Private


(RTTNews.com) - China-based Tibet Pharmaceuticals Inc. (TBET) Monday said it plans to accept a proposal from its Chairman and Chief Executive Officer Hong Yu to take the company private. Yu has offered to buy remaining shares not owned by him for $3.00 a share in cash. Following the news, shares of Tibet are up 150 percent, but still below the offer price.

"In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash," Yu said.

The company noted that the delisting details will be announced shortly.

Yu also denied recent reports published in a website about the company auctioning its operating entity assets. "In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation.," said Yu.

Tibet Pharmaceuticals is an emerging pharmaceutical company engaged in the research and manufacturing of modernized traditional Tibetan medicines in China. The company said it expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries.

TBET is currently at...............

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

http://www.nasdaq.com/article/...-tibet-pharma-private-20120227-01348  

Ich habe mal recherchiert und rausgefunden,dass TBET als IPO und nicht als reverse Merger an die Nasdaq gekommen ist.
Des weiteren macht sich der CEO strafbar ( bedeutet Gefängnisstrafe ) wenn die Aussage mit dem $3 Buyout nicht zutreffend ist.
Das Unternehmen muss jetzt bis spätestens Freitag morgen ein 8k Filing vorlegen.
Mich verblüfft es schon ,dass der Preis nicht bei $2.5-$2.80 steht.
Denke aber das es ein Ausdruck von Unsicherheit bzgl. des Wahrheitsgehalts der News ist.
Die Story zu verfolgen ist auf jeden Fall interessant und man kann da immer was lernen imo...  

Freund von mir in den USA hat mit dem Unternehmen gestern Nacht noch Kontakt aufgenommen und das Unternehmen hat die NEWS mit dem $3 Buyout nocheinmal bestätigt.
Ich werde heute hier einsteigen und mir die Chance auf 80% Gewinn nicht nehmen lassen!  

 

Das 8k Filing bzgl. des Buyouts sollte in den nächsten Tagen veröffentlicht werden. Gem. IR Firm wird das Buyout innerhalb von 2 Monaten abgeschlossen sein!  

From: Fiona Wang shangrilapharm_IR@163
Subject: Re: Question from a shareholder
To: "Kurt Slade"
Date: Wednesday, February 29, 2012, 7:01 AM


the 8k will come out soon.
在 2012-2-29，下午10:58， Kurt Slade 写道：


Investor Relations
Fiona Wang  

 

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8452845  

bekomme ich noch welche? ;)  

Aktie ist momentan in den Händen von Shorties.
Ich rechne damit, dass das Buyout mindestens 2 Monate dauern wird.
Bis dahin bleibt TBET ein Spielball der Shorties.  

http://seekingalpha.com/article/...-that-is-going-private?source=feed  

TBET Security deletion from NASDAQ / CQS as of today

TBET wird dann wohl den Handel bei den Pinks aufnehmen...